physIQ Announces Collaboration with InCarda Therapeutics and Syneos Health


physIQ has announced a strategic collaboration with InCarda Therapeutics, Inc. Syneos Health recommended physIQ’s monitoring solution to help advance InCarda’s clinical study of InRhythm™ (orally inhaled flecainide) in patients with atrial fibrillation.

Read more about the new partnership here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.